MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy

<p>Abstract</p> <p>Background</p> <p>The CD133 antigen is a marker of radio- and chemo-resistant stem cell populations in glioblastoma (GBM). The O<sup>6</sup>-methylguanine DNA methyltransferase (MGMT) enzyme is related with temozolomide (TMZ) resistance. O...

Full description

Bibliographic Details
Published in:Journal of Translational Medicine
Main Authors: Melguizo Consolación, Prados Jose, González Beatriz, Ortiz Raul, Concha Angel, Alvarez Pablo, Madeddu Roberto, Perazzoli Gloria, Oliver Jaime, López Rodrigo, Rodríguez-Serrano Fernando, Aránega Antonia
Format: Article
Language:English
Published: BMC 2012-12-01
Subjects:
Glioblastoma
Radiotherapy
Temozolomide
MGMT
Methylation
CD133
Online Access:http://www.translational-medicine.com/content/10/1/250

Internet

http://www.translational-medicine.com/content/10/1/250

Similar Items